Prothena (PRTA) PT Lowered to $50.00

Prothena (NASDAQ:PRTA) had its price target lowered by Barclays from $70.00 to $50.00 in a report issued on Thursday. The brokerage presently has an “overweight” rating on the biotechnology company’s stock. Barclays’ target price would indicate a potential upside of 26.55% from the stock’s previous close.

A number of other equities research analysts have also recently commented on the stock. ValuEngine raised shares of Prothena from a “sell” rating to a “hold” rating in a report on Wednesday. BidaskClub raised shares of Prothena from a “sell” rating to a “hold” rating in a report on Friday, March 23rd. Deutsche Bank reaffirmed a “buy” rating on shares of Prothena in a report on Wednesday, March 21st. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $69.00 target price on shares of Prothena in a report on Wednesday, March 21st. Finally, Oppenheimer set a $70.00 target price on shares of Prothena and gave the company a “buy” rating in a report on Wednesday, March 21st. Four analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $72.83.

How to Become a New Pot Stock Millionaire

Shares of NASDAQ:PRTA opened at $39.51 on Thursday. Prothena has a one year low of $27.19 and a one year high of $70.00. The stock has a market capitalization of $1,704.93, a PE ratio of -9.71 and a beta of 2.70.

Prothena (NASDAQ:PRTA) last announced its earnings results on Wednesday, February 14th. The biotechnology company reported ($1.24) EPS for the quarter, beating analysts’ consensus estimates of ($1.48) by $0.24. Prothena had a negative net margin of 556.84% and a negative return on equity of 33.37%. The business had revenue of $0.23 million during the quarter, compared to analysts’ expectations of $0.27 million. During the same period in the prior year, the company earned ($1.41) earnings per share. The business’s revenue was up 33.9% compared to the same quarter last year. sell-side analysts anticipate that Prothena will post -5.34 EPS for the current fiscal year.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Fieldpoint Private Securities LLC purchased a new position in Prothena during the third quarter worth about $162,000. First Trust Advisors LP purchased a new position in Prothena during the third quarter worth about $212,000. HBK Investments L P purchased a new position in Prothena during the fourth quarter worth about $213,000. Jefferies Group LLC purchased a new position in Prothena during the fourth quarter worth about $292,000. Finally, Capital Fund Management S.A. purchased a new position in Prothena during the fourth quarter worth about $330,000.

ILLEGAL ACTIVITY NOTICE: “Prothena (PRTA) PT Lowered to $50.00” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright law. The correct version of this report can be read at https://www.dispatchtribunal.com/2018/04/07/prothena-prta-pt-lowered-to-50-00.html.

About Prothena

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on the discovery, development, and commercialization of novel immunotherapies for the treatment of diseases in the neuroscience and orphan categories. The company is developing antibody-based product candidates that include NEOD001, a monoclonal antibody that is in Phase III and Phase IIb clinical trials for the treatment of AL amyloidosis; PRX002/RG7935 that is in Phase II clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, a monoclonal antibody that is under preclinical development for the treatment of ATTR Amyloidosis.

Analyst Recommendations for Prothena (NASDAQ:PRTA)

Receive News & Ratings for Prothena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply